Literature DB >> 3062060

Regional haemodynamic effects of neuropeptide Y, vasopressin and angiotensin II in conscious, unrestrained, Long Evans and Brattleboro rats.

S M Gardiner1, T Bennett, A M Compton.   

Abstract

The regional haemodynamic responses to equipressor doses of neuropeptide Y (NPY), vasopressin (AVP) and angiotensin II (AII) were assessed in conscious Long Evans and Brattleboro rats, chronically instrumented with miniaturized, pulsed Doppler probes. NPY caused particularly potent renal vasoconstrictions in intact rats of both strains. However, there were differential changes in regional vascular sensitivity of NPY following administration of pentolinium and captopril, indicating that 'buffer' mechanisms were an important determinant of responses to NPY. A marked mesenteric and low renal sensitivity to AVP was seen in both strains in all conditions. AVP was the most potent of the 3 pressor agents, and no evidence was found for it interacting uniquely with buffer mechanisms. The pressor action of AII was offset by a tendency towards hindquarters vasodilatation that was converted to a marked vasoconstriction when pentolinium and captopril were administered. It is feasible that, in the intact rat, AII stimulated adrenal medullary adrenal release which caused beta-adrenoceptor-mediated vasodilatation that acted to offset the direct vasoconstrictor effects of AII.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3062060     DOI: 10.1016/0165-1838(88)90131-2

Source DB:  PubMed          Journal:  J Auton Nerv Syst        ISSN: 0165-1838


  20 in total

1.  Regional haemodynamic responses to infusion of lipopolysaccharide in conscious rats: effects of pre- or post-treatment with glibenclamide.

Authors:  S M Gardiner; P A Kemp; J E March; T Bennett
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

2.  Tonic inhibitory control exerted by opioid peptides in the paraventricular nuclei of the hypothalamus on regional hemodynamic activity in rats.

Authors:  Andrée Lessard; Hélène Bachelard
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

Review 3.  Long-term blood pressure control: is there a set-point in the brain?

Authors:  Yasuhiro Nishida; Megumi Tandai-Hiruma; Takehito Kemuriyama; Kohsuke Hagisawa
Journal:  J Physiol Sci       Date:  2012-05       Impact factor: 2.781

4.  Regional haemodynamic effect of vasopressin infusion in conscious, unrestrained, Brattleboro rats.

Authors:  S M Gardiner; A M Compton; T Bennett
Journal:  Br J Pharmacol       Date:  1989-05       Impact factor: 8.739

5.  Mechanisms contributing to the regional haemodynamic effects of neurotensin in conscious, unrestrained Long Evans rats.

Authors:  H Bachelard; S M Gardiner; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

6.  Cardiovascular responses to angiotensins I and II in normotensive and hypertensive rats; effects of NO synthase inhibition or ET receptor antagonism.

Authors:  S M Gardiner; J E March; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

7.  Cardiovascular responses to retigabine in conscious rats--under normotensive and hypertensive conditions.

Authors:  L V Fretwell; J Woolard
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

8.  The role of vasopressin in the regional vascular responses evoked in the spontaneously breathing rat by systemic hypoxia.

Authors:  A M Louwerse; J M Marshall
Journal:  J Physiol       Date:  1993-10       Impact factor: 5.182

9.  Comparison of the regional haemodynamic effects of the AT1-receptor antagonists, losartan and EXP 3174, in water-deprived Brattleboro rats.

Authors:  R E Widdop; S M Gardiner; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

10.  Regional haemodynamic effects of angiotensin II (3-8) in conscious rats.

Authors:  S M Gardiner; P A Kemp; J E March; T Bennett
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.